April 2026
Addiction
What April 2026's 6 new studies found, synthesized from the papers below. All Addiction research →
The synthesis
Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Addiction, substance use disorder, dependence, alcohol use disorder, opioid use disorder, then ranked by relevance.
Research on addiction in April 2026 is limited and preliminary. A narrative review suggests ibogaine shows promise for substance use disorders but raises serious safety concerns, particularly cardiotoxicity. A preclinical study found that psilocybin did not restore social deficits caused by methamphetamine-fentanyl withdrawal in rats. Overall, the evidence is sparse, mostly preclinical or review-based, and does not support a clear conclusion about the efficacy of psychedelics for addiction.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The Efficacy and Safety of Ibogaine Treatment for Substance Use Disorders - A Narrative Review 2026 | narrative review | Supports | Ibogaine shows promising potential for reducing withdrawal symptoms and cravings in substance use disorders, but serious safety concerns (cardiotoxicity, QT prolongation) exist. | |
| Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations. 2026 | preclinical (animal study) | No effect | Psilocybin pretreatment did not restore social preference deficits caused by methamphetamine-fentanyl polysubstance withdrawal in rats. |
Ibogaine shows promising potential for reducing withdrawal symptoms and cravings in substance use disorders, but serious safety concerns (cardiotoxicity, QT prolongation) exist.
narrative review
Psilocybin pretreatment did not restore social preference deficits caused by methamphetamine-fentanyl polysubstance withdrawal in rats.
preclinical (animal study)
Points of agreement
- Both studies focus on psychedelics (ibogaine, psilocybin) in the context of substance use disorders or withdrawal.
- Both highlight the need for more rigorous research (RCTs, further studies).
Conflicts
- No direct conflicts; the studies address different substances (ibogaine vs. psilocybin) and different outcomes (withdrawal/cravings vs. social behavior).
Gaps
- No human clinical trials on psilocybin for addiction published in April 2026.
- No large-scale RCTs on ibogaine for addiction; safety data is limited.
- Durability of any effects, optimal dosing, and long-term outcomes are unstudied.
- Preclinical findings may not translate to humans.